What's wrong with the FDA? Are safety concerns emphasized at the expense of needed therapies? Are drugs approved too quickly or not fast enough? And whatever your view, who's to blame? A recent segment on CNBC's Squawkbox tries to sort it out with help from Joel Sendek, a Lazard Capital Markets managing director and biotech analyst, and Paul Brown, a consumer healthcare advociate with the Public Interest Research Group.
Click on this link to
watch the video.